Table 1. Percentages of lengthening or shortening on T1 values of the two different cell lines after the treatments with SKF-96365 or Verapamil, respectively.

Treatments	MDA-MB-231Br metastatic cells	U87-MG glioma cells
SKF-96365	↑ 44% ± 3.5	↑ 49% ± 8
Verapamil	↓ 34.1% ± 8.3	2.7% ± 4.8

The T1 of MDA-MB-231Br cells and U87-MG cells at baseline were 2202 ± 78.9 ms and 2043.5 ± 138.2 ms, respectively.